Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer

J Clin Oncol. 2011 Dec 20;29(36):4845. doi: 10.1200/JCO.2011.38.8777. Epub 2011 Nov 14.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Humans
  • Pyrimidines / administration & dosage*
  • Quinazolines / administration & dosage*
  • Sulfonamides / administration & dosage*
  • Uterine Cervical Neoplasms / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Pyrimidines
  • Quinazolines
  • Sulfonamides